A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes
Primary result · HbA1cResult — go to the resultMean adjusted difference −0.6 percentage points 95% CI −0.8 to −0.4Authors' conclusion
In this 13-week, randomized, controlled trial involving adults with insulin-treated type 2 diabetes, AID was associated with a greater reduction in glycated hemoglobin levels than CGM alone.
Study context
- Population
- Adults with insulin-treated T2Drandomized 2:1
- Participants
- 319 adults
- Comparison
- Automated insulin delivery (AID) vs continuation of pretrial insulin-delivery method; both with continuous glucose monitoring (CGM)
- Primary endpoint
- Glycated hemoglobin level
- Follow-up
- 13 weeks
Methodological detailsmulticentre
- Multicentre
Primary result
HbA1c
Mean adjusted difference
−0.6 percentage points
95% CI −0.8 to −0.4
P < 0.001
By group
AIDvs Control
mean adjusted difference −0.6 percentage points (95% CI −0.8 to −0.4); P < 0.001
As reported in the abstract
Further findings
| Outcome | AID | Control | Mean difference (percentage points) (95% CI) | P value | |
|---|---|---|---|---|---|
| Time in target glucose range 70–180 mg/dL (TIR) · 13 weeks | mean 64 ± 16 % | mean 52 ± 21 % | 14 (11–17) | P < 0.001 | |
| Baseline | 48±24% | 51±21% | |||
| −1001020Difference, percentage points (linear scale) |
Other multiplicity-controlled CGM hyperglycemia outcomes
- All significantly better with AID than control
Safety
| Outcome | AID |
|---|---|
| Hypoglycemia | |
| Severe hypoglycemia event | one patient |
Hypoglycemia
- CGM-measured hypoglycemia frequency low in both groups
Original publication
A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes. N Engl J Med. Published 19 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →